Green Karat Secures EU-GMP Certification for International Expansion

Green Karat Secures EU-GMP Certification for International Expansion

October 5, 2026 | David Brown –

Quebec-based cannabis company Green Karat received its EU-GMP certification on October 1, 2026, marking what the company calls a significant milestone in its journey. 

EU GMP or an equivalent pharmaceutical standard is required for medical cannabis products sold in export markets like Germany, the United Kingdom, and Australia. Many Canadian companies have turned to the export market to address a domestic market with ample supply. 

Founded by Paul‑Eric Taisne and Jen‑Frederick Nadeau, and licensed by Health Canada since 2020, Green Karat focuses on hand-trimmed, craft products that it sells in Canada, the EU, the UK, Israel, and Australia. Green Karat (9385-1756 Quebec Inc.) also partners with Cantourage Germany and Cantourage Clinics UK.

“Reaching this level of international compliance is an important recognition of that vision and the standards we have worked to establish from day one,” a company spokesperson noted in an email to StratCann. “This achievement belongs above all to our team.

“We want to give special recognition to Ms. Kim Supple, our Head of Quality Assurance and export specialist. Kim led this complex project with exceptional discipline, expertise and determination. Her outstanding work was instrumental in navigating every stage of the certification process and bringing it successfully to completion.

“We dedicate months to cultivating, drying and curing each flower to exacting standards. Everything that follows must preserve its quality, consistency and unique characteristics so that it reaches patients exactly as we intended,” they continued. “EU-GMP opens an important new chapter for Green Karat. It strengthens our ability to serve international markets while maintaining close oversight of our products throughout their journey from our facility to patients.

“This certification is both a recognition of how far we have come and a foundation for what comes next. A special thank-you to Cantourage for acting as our sponsor throughout the process, as well as to Sven Kruse Pharma Consulting for its valuable guidance and support along the way.”

Canadian cannabis has dominated the international medical markets in jurisdictions like the UK, Germany, Australia, and Israel in recent years. 

Between 2021 and 2024, regular monthly exports of cannabis for medical purposes from Canada typically ranged between 2,500 kg and 14,000 kg. Starting in February 2025, exports settled at a new baseline above 20,000 kg a month, reaching a record average of around 33,800 kg/month in 2026.

According to Statistics Canada, through the first seven months of 2026, Canada exported 236,822 kg of medical/scientific cannabis. Germany accounted for 39% of those shipments (92,147 kg), Australia for 18% (42,216 kg), Portugal for 15%, Czechia for 10%, Israel for 8%, and the UK for 6%.